beta

CRVS

Corvus Pharmaceuticals Inc.

Crvs

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 03-06-2019 11-01-2018 08-02-2018 05-03-2018 03-01-2018 11-02-2017 08-03-2017 05-04-2017
Actual EPS -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.36 -0.4 -0.63 -0.58 -0.62 -0.73 -0.79
Consensus EPS -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.46 -0.63 -0.71 -0.66 -0.85
Estimated EPS -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.4 -0.46 -0.63 -0.71 -0.66 -0.85
Number of Estimates 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1
EPS Surprise $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.04 $0.10 $0.23 $0.08 $0.08 $0.23

Stats

Summary

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It is engaged in development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells.

Market Cap: 207 Million

Primary Exchange: NASDAQ Global Market

Website: http://www.corvuspharma.com

Shares Outstanding: 21 Million

Float: 20.9 Million

Dividend: 0.0 (0.0%)

Beta: -1.53218

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 1.02 Million

Ethical Flags

Animal testing

Longest drawdown: 833 trading days

From: 2017-03-27 To: 2019-06-12

Lowest Point:

Apple's WWDC, DuPont's Return And Tariff Anxiety (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-02 03:35:19:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Apple's WWDC, DuPont's Return And Tariff Anxiety (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-02 03:35:19:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Apple's WWDC, DuPont's Return And Tariff Anxiety (Stocks To Watch Podcast)

via: SeekingAlpha at 2019-06-02 03:35:19:000

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you can re… read more...

Stocks To Watch: Apple's WWDC, DuPont's Return And Tariff Anxiety

via: SeekingAlpha at 2019-06-01 04:45:33:000

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. The week ahead sees Apple (AAPL) host its annual WWDC conference, Walmart (WMT) hol… read more...

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-12 19:00:13:000

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2019 Earnings Conference Call May 9, 2019 16:30 ET Company Participants Zack Kubow - IR, Pure Communications Leiv Lea - CFO Richard Miller - President & CEO Conference Call Participants Biren Amin - Jefferies Michael Vincent Mora… read more...

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-12 19:00:13:000

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2019 Earnings Conference Call May 9, 2019 16:30 ET Company Participants Zack Kubow - IR, Pure Communications Leiv Lea - CFO Richard Miller - President & CEO Conference Call Participants Biren Amin - Jefferies Michael Vincent Mora… read more...

Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q1 2019 Results - Earnings Call Transcript

via: SeekingAlpha at 2019-05-12 19:00:13:000

Corvus Pharmaceuticals, Inc. (CRVS) Q1 2019 Earnings Conference Call May 9, 2019 16:30 ET Company Participants Zack Kubow - IR, Pure Communications Leiv Lea - CFO Richard Miller - President & CEO Conference Call Participants Biren Amin - Jefferies Michael Vincent Mora… read more...

Corvus Pharmaceuticals EPS in-line

via: SeekingAlpha at 2019-05-09 12:47:51:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q1 GAAP EPS of -$0.40 in-line. More news on: Corvus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals EPS in-line

via: SeekingAlpha at 2019-05-09 12:47:51:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q1 GAAP EPS of -$0.40 in-line. More news on: Corvus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals EPS in-line

via: SeekingAlpha at 2019-05-09 12:47:51:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q1 GAAP EPS of -$0.40 in-line. More news on: Corvus Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals: In The Spotlight

via: SeekingAlpha at 2019-05-06 10:02:41:000

"Whether a man is a criminal or a public servant is purely a matter of perspective . Tom Robbins, Another Roadside Attraction Today, we take a look at a 'Busted IPO' in the biotech space. The stock has not rewarded its shareholders since it debuted several years ago, but … read more...

Corvus Pharmaceuticals: In The Spotlight

via: SeekingAlpha at 2019-05-06 10:02:41:000

"Whether a man is a criminal or a public servant is purely a matter of perspective . Tom Robbins, Another Roadside Attraction Today, we take a look at a 'Busted IPO' in the biotech space. The stock has not rewarded its shareholders since it debuted several years ago, but … read more...

Corvus Pharmaceuticals: In The Spotlight

via: SeekingAlpha at 2019-05-06 10:02:41:000

"Whether a man is a criminal or a public servant is purely a matter of perspective . Tom Robbins, Another Roadside Attraction Today, we take a look at a 'Busted IPO' in the biotech space. The stock has not rewarded its shareholders since it debuted several years ago, but … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals (CRVS) Presents At Cowen and Company 39th Annual Health Care Conference - Slideshow

via: SeekingAlpha at 2019-03-12 10:26:24:000

The following slide deck was published by Corvus Pharmaceuticals, Inc. in conjunction with this Read more … read more...

Corvus Pharmaceuticals beats by $0.04

via: SeekingAlpha at 2019-03-07 11:44:39:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q4 GAAP EPS of -$0.36 beats by $0.04 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals beats by $0.04

via: SeekingAlpha at 2019-03-07 11:44:39:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q4 GAAP EPS of -$0.36 beats by $0.04 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals beats by $0.04

via: SeekingAlpha at 2019-03-07 11:44:39:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q4 GAAP EPS of -$0.36 beats by $0.04 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-02-01 09:12:13:000

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-02-01 09:12:13:000

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-02-01 09:12:13:000

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-02-01 09:12:13:000

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-02-01 09:12:13:000

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-02-01 04:12:13:000

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-02-01 04:12:13:000

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-02-01 04:12:13:000

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more … read more...

Key events next week - healthcare

via: SeekingAlpha at 2019-02-01 04:12:13:000

Noteworthy events during the week of February 3 - 9 for healthcare investors. More news on: AVROBIO, Amicus Therapeutics, Inc., Protalix BioTherapeutics, Inc, Healthcare stocks news, , Read more … read more...

Oncology players in the red on Celgene deal

via: SeekingAlpha at 2019-01-03 10:41:47:000

A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb announced its $74B bid for Celgene, thereby removing a top candidate from the list of potential suitors. More news on: NewLink Genetics Corporation, Corvus Pharmaceuticals, Nektar Therapeuti… read more...

Oncology players in the red on Celgene deal

via: SeekingAlpha at 2019-01-03 10:41:47:000

A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb announced its $74B bid for Celgene, thereby removing a top candidate from the list of potential suitors. More news on: NewLink Genetics Corporation, Corvus Pharmaceuticals, Nektar Therapeuti… read more...

Oncology players in the red on Celgene deal

via: SeekingAlpha at 2019-01-03 10:41:47:000

A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb announced its $74B bid for Celgene, thereby removing a top candidate from the list of potential suitors. More news on: NewLink Genetics Corporation, Corvus Pharmaceuticals, Nektar Therapeuti… read more...

Oncology players in the red on Celgene deal

via: SeekingAlpha at 2019-01-03 10:41:47:000

A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb announced its $74B bid for Celgene, thereby removing a top candidate from the list of potential suitors. More news on: NewLink Genetics Corporation, Corvus Pharmaceuticals, Nektar Therapeuti… read more...

Oncology players in the red on Celgene deal

via: SeekingAlpha at 2019-01-03 10:41:47:000

A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb announced its $74B bid for Celgene, thereby removing a top candidate from the list of potential suitors. More news on: NewLink Genetics Corporation, Corvus Pharmaceuticals, Nektar Therapeuti… read more...

Oncology players in the red on Celgene deal

via: SeekingAlpha at 2019-01-03 10:41:47:000

A wide range of oncology companies are under modest pressure after deal-hungry Bristol-Myers Squibb announced its $74B bid for Celgene, thereby removing a top candidate from the list of potential suitors. More news on: NewLink Genetics Corporation, Corvus Pharmaceuticals, Nektar Therapeuti… read more...

Corvus Pharmaceuticals beats by $0.10

via: SeekingAlpha at 2018-11-01 17:20:31:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q3 GAAP EPS of -$0.36 beats by $0.10. More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals beats by $0.10

via: SeekingAlpha at 2018-11-01 17:20:31:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q3 GAAP EPS of -$0.36 beats by $0.10. More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals beats by $0.10

via: SeekingAlpha at 2018-11-01 17:20:31:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q3 GAAP EPS of -$0.36 beats by $0.10. More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals beats by $0.10

via: SeekingAlpha at 2018-11-01 17:20:31:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q3 GAAP EPS of -$0.36 beats by $0.10. More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals beats by $0.10

via: SeekingAlpha at 2018-11-01 17:20:31:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q3 GAAP EPS of -$0.36 beats by $0.10. More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals beats by $0.10

via: SeekingAlpha at 2018-11-01 17:20:31:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q3 GAAP EPS of -$0.36 beats by $0.10. More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus Pharmaceuticals beats by $0.10

via: SeekingAlpha at 2018-11-01 17:20:31:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q3 GAAP EPS of -$0.36 beats by $0.10. More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more … read more...

Corvus up 1% on encouraging biomarker data

via: SeekingAlpha at 2018-10-22 14:11:17:000

Thinly traded micro cap Corvus Pharmaceuticals ( CRVS +1.4% ) is up on below-average volume on the heels of its announcement of new data on a biomarker associated with patient response to CPI-444 , an adenosine A2A receptor antagonist. The results were presented as ESMO in Munich. Mor… read more...

Corvus up 1% on encouraging biomarker data

via: SeekingAlpha at 2018-10-22 14:11:17:000

Thinly traded micro cap Corvus Pharmaceuticals ( CRVS +1.4% ) is up on below-average volume on the heels of its announcement of new data on a biomarker associated with patient response to CPI-444 , an adenosine A2A receptor antagonist. The results were presented as ESMO in Munich. Mor… read more...

Corvus up 1% on encouraging biomarker data

via: SeekingAlpha at 2018-10-22 14:11:17:000

Thinly traded micro cap Corvus Pharmaceuticals ( CRVS +1.4% ) is up on below-average volume on the heels of its announcement of new data on a biomarker associated with patient response to CPI-444 , an adenosine A2A receptor antagonist. The results were presented as ESMO in Munich. Mor… read more...

Corvus Pharmaceuticals beats by $0.19

via: SeekingAlpha at 2018-08-02 17:13:20:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q2 EPS of -$0.40 beats by $0.19 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Corvus Pharmaceuticals beats by $0.19

via: SeekingAlpha at 2018-08-02 17:13:20:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q2 EPS of -$0.40 beats by $0.19 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Corvus Pharmaceuticals beats by $0.19

via: SeekingAlpha at 2018-08-02 17:13:20:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q2 EPS of -$0.40 beats by $0.19 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Corvus Pharmaceuticals beats by $0.19

via: SeekingAlpha at 2018-08-02 17:13:20:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q2 EPS of -$0.40 beats by $0.19 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Corvus Pharmaceuticals beats by $0.19

via: SeekingAlpha at 2018-08-02 17:13:20:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q2 EPS of -$0.40 beats by $0.19 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Corvus Pharmaceuticals beats by $0.19

via: SeekingAlpha at 2018-08-02 17:13:20:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q2 EPS of -$0.40 beats by $0.19 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Corvus Pharmaceuticals beats by $0.19

via: SeekingAlpha at 2018-08-02 17:13:20:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q2 EPS of -$0.40 beats by $0.19 . More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more … read more...

Company Profile: Surface Oncology

via: SeekingAlpha at 2018-07-22 13:44:37:000

Surface Oncology (SURF) is a clinical-stage biopharmaceutical company with clinical assets targeting CD47 and CD73. If you are a new investor to the CD47 story, I recommend you start here . Clinical Pipeline SURF has two compounds in ongoing phase 1 trials, SRF-231 and SRF-373, with two m… read more...

Company Profile: Surface Oncology

via: SeekingAlpha at 2018-07-22 13:44:37:000

Surface Oncology (SURF) is a clinical-stage biopharmaceutical company with clinical assets targeting CD47 and CD73. If you are a new investor to the CD47 story, I recommend you start here . Clinical Pipeline SURF has two compounds in ongoing phase 1 trials, SRF-231 and SRF-373, with two m… read more...

Company Profile: Surface Oncology

via: SeekingAlpha at 2018-07-22 13:44:37:000

Surface Oncology (SURF) is a clinical-stage biopharmaceutical company with clinical assets targeting CD47 and CD73. If you are a new investor to the CD47 story, I recommend you start here . Clinical Pipeline SURF has two compounds in ongoing phase 1 trials, SRF-231 and SRF-373, with two m… read more...

Company Profile: Surface Oncology

via: SeekingAlpha at 2018-07-22 13:44:37:000

Surface Oncology (SURF) is a clinical-stage biopharmaceutical company with clinical assets targeting CD47 and CD73. If you are a new investor to the CD47 story, I recommend you start here . Clinical Pipeline SURF has two compounds in ongoing phase 1 trials, SRF-231 and SRF-373, with two m… read more...

Corvus Pharmaceuticals Remains A High-Risk Investment

via: SeekingAlpha at 2018-06-26 14:49:51:000

On June 5, 2018, Jefferies established a price target of $17 per share for Corvus Pharmaceuticals (CRVS). As I started researching this article on Friday, June 22, Corvus was down 10% on the day to $11.25. Who is right, the market or Jefferies? Or neither? As a small cap biotech investor, ma… read more...

Corvus Pharmaceuticals Remains A High-Risk Investment

via: SeekingAlpha at 2018-06-26 14:49:51:000

On June 5, 2018, Jefferies established a price target of $17 per share for Corvus Pharmaceuticals (CRVS). As I started researching this article on Friday, June 22, Corvus was down 10% on the day to $11.25. Who is right, the market or Jefferies? Or neither? As a small cap biotech investor, ma… read more...

Corvus Pharmaceuticals Remains A High-Risk Investment

via: SeekingAlpha at 2018-06-26 14:49:51:000

On June 5, 2018, Jefferies established a price target of $17 per share for Corvus Pharmaceuticals (CRVS). As I started researching this article on Friday, June 22, Corvus was down 10% on the day to $11.25. Who is right, the market or Jefferies? Or neither? As a small cap biotech investor, ma… read more...

Corvus Pharmaceuticals Remains A High-Risk Investment

via: SeekingAlpha at 2018-06-26 14:49:51:000

On June 5, 2018, Jefferies established a price target of $17 per share for Corvus Pharmaceuticals (CRVS). As I started researching this article on Friday, June 22, Corvus was down 10% on the day to $11.25. Who is right, the market or Jefferies? Or neither? As a small cap biotech investor, ma… read more...

Corvus Pharmaceuticals Remains A High-Risk Investment

via: SeekingAlpha at 2018-06-26 14:49:51:000

On June 5, 2018, Jefferies established a price target of $17 per share for Corvus Pharmaceuticals (CRVS). As I started researching this article on Friday, June 22, Corvus was down 10% on the day to $11.25. Who is right, the market or Jefferies? Or neither? As a small cap biotech investor, ma… read more...

Week 26 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-06-24 00:40:35:000

Breakout Forecast Selections for Week 26: Market conditions continue with medium volatility. The positive momentum gauge continues with another full week in yellow (medium) unchanged from a value of 44 at the end of the prior week. The all time low for the positive momentum selection gaug… read more...

Week 26 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-06-24 00:40:35:000

Breakout Forecast Selections for Week 26: Market conditions continue with medium volatility. The positive momentum gauge continues with another full week in yellow (medium) unchanged from a value of 44 at the end of the prior week. The all time low for the positive momentum selection gaug… read more...

Week 25 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-06-18 01:15:42:000

Breakout Forecast Selections for Week 25: Market conditions continue with high volatility. The positive momentum gauge continues with another full week in yellow (medium) moving from a value of 60 at the end of the prior week down to a value of 44 this week. The all time low for the posit… read more...

Week 25 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-06-18 01:15:42:000

Breakout Forecast Selections for Week 25: Market conditions continue with high volatility. The positive momentum gauge continues with another full week in yellow (medium) moving from a value of 60 at the end of the prior week down to a value of 44 this week. The all time low for the posit… read more...

Week 25 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-06-18 01:15:42:000

Breakout Forecast Selections for Week 25: Market conditions continue with high volatility. The positive momentum gauge continues with another full week in yellow (medium) moving from a value of 60 at the end of the prior week down to a value of 44 this week. The all time low for the posit… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

A High-Throughput Screen For Cancer Stocks That Have Few (Or No) Fundamentals

via: SeekingAlpha at 2018-06-16 09:00:00:000

Author's note: This article was presented early to subscribers of the Total Pharma Tracker , and they also got further insight into how best to use these tools in making investment decisions. Biotech holds a special place in my heart, both for the way it captures the imagination and for… read more...

Institutional Top Ideas Series: Biotechnology Value Fund

via: SeekingAlpha at 2018-06-04 09:19:47:000

In the last entry of this series, we took a look at top ideas from Perceptive Advisors, a hedge fund with a highly enviable track record characterized by impressive consistency and high returns. Going forward, I hope to continue to delve into the portfolios of successful hedge funds predo… read more...

Institutional Top Ideas Series: Biotechnology Value Fund

via: SeekingAlpha at 2018-06-04 09:19:47:000

In the last entry of this series, we took a look at top ideas from Perceptive Advisors, a hedge fund with a highly enviable track record characterized by impressive consistency and high returns. Going forward, I hope to continue to delve into the portfolios of successful hedge funds predo… read more...

Institutional Top Ideas Series: Biotechnology Value Fund

via: SeekingAlpha at 2018-06-04 09:19:47:000

In the last entry of this series, we took a look at top ideas from Perceptive Advisors, a hedge fund with a highly enviable track record characterized by impressive consistency and high returns. Going forward, I hope to continue to delve into the portfolios of successful hedge funds predo… read more...

Week 21 Breakout Forecast: Short-Term Picks To Give You An Edge

via: SeekingAlpha at 2018-05-20 20:24:19:000

Breakout Forecast Selections for Week 21 Market conditions continue with high volatility. The positive momentum gauge spent another full week in yellow (medium), moving from a value of 66 last week up to a value of 73 this week. The all-time low for the positive momentum selection gauge is 8… read more...

3 Things In Biotech, April 30: Another ADC, Another Breakthrough, Another Immunotherapy

via: SeekingAlpha at 2018-05-01 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

3 Things In Biotech, April 30: Another ADC, Another Breakthrough, Another Immunotherapy

via: SeekingAlpha at 2018-05-01 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

3 Things In Biotech, April 30: Another ADC, Another Breakthrough, Another Immunotherapy

via: SeekingAlpha at 2018-05-01 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

3 Things In Biotech, April 30: Another ADC, Another Breakthrough, Another Immunotherapy

via: SeekingAlpha at 2018-05-01 08:00:00:000

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech You Should Learn Today," a… read more...

Surface Oncology Proposes IPO Terms

via: SeekingAlpha at 2018-04-09 12:40:49:000

Quick Take Surface Oncology ( SURF ) aims to raise $84 million in a U.S. IPO of its common stock, according to an amended S-1/A registration statement . The company has a pipeline of cancer treatment drug candidates focused on affecting the tumor microenvironment. SURFs lead c… read more...

Surface Oncology Proposes IPO Terms

via: SeekingAlpha at 2018-04-09 12:40:49:000

Quick Take Surface Oncology ( SURF ) aims to raise $84 million in a U.S. IPO of its common stock, according to an amended S-1/A registration statement . The company has a pipeline of cancer treatment drug candidates focused on affecting the tumor microenvironment. SURFs lead c… read more...

Surface Oncology Proposes IPO Terms

via: SeekingAlpha at 2018-04-09 12:40:49:000

Quick Take Surface Oncology ( SURF ) aims to raise $84 million in a U.S. IPO of its common stock, according to an amended S-1/A registration statement . The company has a pipeline of cancer treatment drug candidates focused on affecting the tumor microenvironment. SURFs lead c… read more...

Surface Oncology Proposes IPO Terms

via: SeekingAlpha at 2018-04-09 12:40:49:000

Quick Take Surface Oncology ( SURF ) aims to raise $84 million in a U.S. IPO of its common stock, according to an amended S-1/A registration statement . The company has a pipeline of cancer treatment drug candidates focused on affecting the tumor microenvironment. SURFs lead c… read more...

Surface Oncology Files For $75 Million IPO

via: SeekingAlpha at 2018-04-05 08:36:42:000

Quick Take Surface Oncology ( SURF ) intends to sell shares of its common stock for gross proceeds of $75 million from a U.S. IPO, according to an S-1 registration statement . The firm is a clinical-stage immuno-oncology company developing next-generation antibody therapies that targe… read more...

Surface Oncology Files For $75 Million IPO

via: SeekingAlpha at 2018-04-05 08:36:42:000

Quick Take Surface Oncology ( SURF ) intends to sell shares of its common stock for gross proceeds of $75 million from a U.S. IPO, according to an S-1 registration statement . The firm is a clinical-stage immuno-oncology company developing next-generation antibody therapies that targe… read more...

Surface Oncology Files For $75 Million IPO

via: SeekingAlpha at 2018-04-05 08:36:42:000

Quick Take Surface Oncology ( SURF ) intends to sell shares of its common stock for gross proceeds of $75 million from a U.S. IPO, according to an S-1 registration statement . The firm is a clinical-stage immuno-oncology company developing next-generation antibody therapies that targe… read more...

Surface Oncology Files For $75 Million IPO

via: SeekingAlpha at 2018-04-05 08:36:42:000

Quick Take Surface Oncology ( SURF ) intends to sell shares of its common stock for gross proceeds of $75 million from a U.S. IPO, according to an S-1 registration statement . The firm is a clinical-stage immuno-oncology company developing next-generation antibody therapies that targe… read more...

Corvus Pharmaceuticals: A New Immunotherapy Player

via: SeekingAlpha at 2018-04-04 08:37:29:000

The immune checkpoints are signaling molecules that act to shut down or block an immune response. In a healthy person, this mechanism is a "safety" feature allowing cessation of the immune response once it has performed its task. Cytotoxic T Lymphocyte Antigen 4 (CTLA4) and programd D… read more...

Corvus Pharmaceuticals: A New Immunotherapy Player

via: SeekingAlpha at 2018-04-04 08:37:29:000

The immune checkpoints are signaling molecules that act to shut down or block an immune response. In a healthy person, this mechanism is a "safety" feature allowing cessation of the immune response once it has performed its task. Cytotoxic T Lymphocyte Antigen 4 (CTLA4) and programd D… read more...

Corvus Pharmaceuticals: A New Immunotherapy Player

via: SeekingAlpha at 2018-04-04 08:37:29:000

The immune checkpoints are signaling molecules that act to shut down or block an immune response. In a healthy person, this mechanism is a "safety" feature allowing cessation of the immune response once it has performed its task. Cytotoxic T Lymphocyte Antigen 4 (CTLA4) and programd D… read more...

Corvus Pharmaceuticals: A New Immunotherapy Player

via: SeekingAlpha at 2018-04-04 08:37:29:000

The immune checkpoints are signaling molecules that act to shut down or block an immune response. In a healthy person, this mechanism is a "safety" feature allowing cessation of the immune response once it has performed its task. Cytotoxic T Lymphocyte Antigen 4 (CTLA4) and programd D… read more...

Daily Insider Ratings Round Up 3/14/18: CRVS, ECL, NMFC, BDGE, AAT, TEI, WTTR

via: SeekingAlpha at 2018-03-15 20:07:50:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/14/18: CRVS, ECL, NMFC, BDGE, AAT, TEI, WTTR

via: SeekingAlpha at 2018-03-15 20:07:50:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/14/18: CRVS, ECL, NMFC, BDGE, AAT, TEI, WTTR

via: SeekingAlpha at 2018-03-15 20:07:50:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/14/18: CRVS, ECL, NMFC, BDGE, AAT, TEI, WTTR

via: SeekingAlpha at 2018-03-15 20:07:50:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/13/18: VRX, CRVS, NIHD, ETM, LGCY, ECL, PK

via: SeekingAlpha at 2018-03-15 12:20:57:000

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/13/18: VRX, CRVS, NIHD, ETM, LGCY, ECL, PK

via: SeekingAlpha at 2018-03-15 12:20:57:000

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/13/18: VRX, CRVS, NIHD, ETM, LGCY, ECL, PK

via: SeekingAlpha at 2018-03-15 12:20:57:000

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/13/18: VRX, CRVS, NIHD, ETM, LGCY, ECL, PK

via: SeekingAlpha at 2018-03-15 12:20:57:000

InsiderInsights' Daily Round-Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/12/18: NMFC, FLDM, DFRG, SCM, TSI, GOGO, CRVS, EGN

via: SeekingAlpha at 2018-03-14 09:09:03:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/12/18: NMFC, FLDM, DFRG, SCM, TSI, GOGO, CRVS, EGN

via: SeekingAlpha at 2018-03-14 09:09:03:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/12/18: NMFC, FLDM, DFRG, SCM, TSI, GOGO, CRVS, EGN

via: SeekingAlpha at 2018-03-14 09:09:03:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Daily Insider Ratings Round Up 3/12/18: NMFC, FLDM, DFRG, SCM, TSI, GOGO, CRVS, EGN

via: SeekingAlpha at 2018-03-14 09:09:03:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi… read more...

Premarket Losers as of 9:05 am (3/8/2018)

via: SeekingAlpha at 2018-03-08 09:19:20:000

VBLT -64% on announcing top-line results from Phase 3 GLOBE study in patients with rGBM. More news on: VBL Therapeutics, CHECKPOINT THERAPEUTICS, ShiftPixy, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (3/8/2018)

via: SeekingAlpha at 2018-03-08 09:19:20:000

VBLT -64% on announcing top-line results from Phase 3 GLOBE study in patients with rGBM. More news on: VBL Therapeutics, CHECKPOINT THERAPEUTICS, ShiftPixy, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (3/8/2018)

via: SeekingAlpha at 2018-03-08 09:19:20:000

VBLT -64% on announcing top-line results from Phase 3 GLOBE study in patients with rGBM. More news on: VBL Therapeutics, CHECKPOINT THERAPEUTICS, ShiftPixy, Stocks on the move, , Read more … read more...

Premarket Losers as of 9:05 am (3/8/2018)

via: SeekingAlpha at 2018-03-08 09:19:20:000

VBLT -64% on announcing top-line results from Phase 3 GLOBE study in patients with rGBM. More news on: VBL Therapeutics, CHECKPOINT THERAPEUTICS, ShiftPixy, Stocks on the move, , Read more … read more...

Arcus Biosciences Files To Raise $100 Million In IPO

via: SeekingAlpha at 2018-02-23 12:24:46:000

Quick Take Arcus Biosciences ( RCUS ) intends to sell shares from its common stock for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is a Phase 1/2 clinical-stage biopharmaceutical company creating cancer immunotherapies. The com… read more...

Arcus Biosciences Files To Raise $100 Million In IPO

via: SeekingAlpha at 2018-02-23 12:24:46:000

Quick Take Arcus Biosciences ( RCUS ) intends to sell shares from its common stock for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is a Phase 1/2 clinical-stage biopharmaceutical company creating cancer immunotherapies. The com… read more...

Arcus Biosciences Files To Raise $100 Million In IPO

via: SeekingAlpha at 2018-02-23 12:24:46:000

Quick Take Arcus Biosciences ( RCUS ) intends to sell shares from its common stock for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is a Phase 1/2 clinical-stage biopharmaceutical company creating cancer immunotherapies. The com… read more...

Arcus Biosciences Files To Raise $100 Million In IPO

via: SeekingAlpha at 2018-02-23 12:24:46:000

Quick Take Arcus Biosciences ( RCUS ) intends to sell shares from its common stock for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is a Phase 1/2 clinical-stage biopharmaceutical company creating cancer immunotherapies. The com… read more...

Nasdaq Biotech Index: 54 to be added, 15 removed

via: SeekingAlpha at 2017-12-11 07:45:08:000

Changes will become effective prior to the open next Monday. ETF: IBB More news on: iShares Nasdaq Biotechnology ETF, Arbutus Biopharma Corp, Aclaris Therapeutics, Healthcare stocks news, News on ETFs, Read more … read more...

Biotech Forum Daily Digest: Behind Omeros' Blowout Results

via: SeekingAlpha at 2017-11-13 14:58:19:000

A cynic is a man who, when he smells flowers, looks around for a coffin . H.L. Mencken The high beta parts of the market continued to take it on the shin while the large cap indices remain placid last week. The S&P 500 and Dow posted small losses on the week as both … read more...

Your Daily Pharma Scoop: Timing Synergy Trade, Valeant's Vyzulta Approved, Seattle Genetics Files SBLA For Adcetris

via: SeekingAlpha at 2017-11-03 14:11:27:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Synergy Pharmaceuticals Today we … read more...

Corvus Pharmaceuticals beats by $0.19

via: SeekingAlpha at 2017-11-02 17:49:10:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q3 EPS of -$0.62 beats by $0.19 . Cash and equivalents of $99.7M. Press Release More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, read more...

Corvus Pharmaceuticals (CRVS) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow

via: SeekingAlpha at 2017-09-28 13:27:31:000

The following slide deck was published by Corvus Pharmaceuticals in conjunction with this Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2017-08-24 08:13:18:000

Zimmer Biomet Holdings (NYSE: ZBH ) initiated with Buy rating by Gabelli. More news on: Zimmer Biomet Holdings, Inc., NeoGenomics Inc., Immune Design, Healthcare stocks news, Stocks on the move, Read more … read more...

Daily Insider Ratings Round Up 6/27/17: JCAP, IFF, EQT, SBPH, YSTR

via: SeekingAlpha at 2017-06-29 00:00:16:000

InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC yesterday. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Significant" in… read more...

Corvus Pharmaceuticals misses by $0.02

via: SeekingAlpha at 2017-05-04 17:51:14:000

Corvus Pharmaceuticals (NASDAQ: CRVS ): Q1 EPS of -$0.79 misses by $0.02 . Cash and equivalents $122.1M Press Release More news on: Corvus Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , read more...

3 Things In Biotech You Should Learn Today: May 3, 2017

via: SeekingAlpha at 2017-05-03 12:24:38:000

Welcome to another edition of "3 Things in Biotech You Should Learn Today," a daily digest covering the world of biotechnology and pharma news. The goal of this publication is to help you keep pace with the whirlwind of new results and developments in this industry. First, an announcement: d… read more...

Biotech Forum Daily Digest: Biotech Remains Stuck. Hospital Stocks Surge. Spotlight On Heron Therapeutics

via: SeekingAlpha at 2017-05-03 08:17:15:000

" Be kind, for everyone you meet is fighting a harder battle ." Plato "Deja Vu All Over Again" Yogi Berra Stop me if you have heard this one before… The main biotech indices are once again right up against stubborn upward resistance levels that have proved to be a hard ... read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX